ondansetron nasal (NS003)
/ Nasus Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 10, 2026
A Study to Compare the Bioavailability of Ondansetron Following Nasal (NS003) and IV Administration in Healthy Adults
(clinicaltrials.gov)
- P1 | N=12 | Recruiting | Sponsor: Nasus Pharma
New P1 trial • Chemotherapy-Induced Nausea and Vomiting
1 to 1
Of
1
Go to page
1